Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

KIF18A inhibitor GH2616

An orally bioavailable inhibitor of the human kinesin-like protein KIF18A, with potential antineoplastic activity. Upon oral administration, KIF18A inhibitor GH2616 selectively binds to and inhibits the activity of KIF18A. This may result in multipolar cell division and inhibit tumor cell proliferation. KIF18A, a mitotic kinesin-8 motor protein, plays an important role in the regulation of chromosome positioning during cell division and is overexpressed in certain cancers. Certain cancer cells with chromosomal instability (CIN) features depend on KIF18A activity for bipolar spindle integrity and cell proliferation.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Code name:GH 2616
GH-2616
GH2616
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search